HELP Therapeutics’ iPSC-derived cardiomyocytes improved walking distance, myocardial perfusion and heart wall thickening when added to bypass surgery in a 20-patient randomized trial.
The company's lead program, HS-001, required open heart surgery, while the new innovation allows for a much simpler, less invasive administration.
Trailhead Biosystems has launched a functionally validated, highly pure iPSC-derived endothelial cell product designed to give researchers a scalable, reproducible human vascular model for angiogenesis, inflammation, drug screening and toxicity studies.
With the right secured for stem cell potency, Longeveron is continuing its path forward with clinical trials for several mesenchymal stem cell indications.
The new platforms aim to streamline large-scale production of iPSC-derived cell therapies for new indications.
Researchers are testing a minimally invasive stem cell patch that could reduce the need for transplants.
What appeared to be a potential stem cell breakthrough is slowly being torn apart by peer-reviewers, who found damning inconsistencies in the data.
The Phase 2 study showed good results for placenta-derived cell therapy for diabetic foot ulcers complicated by PAD.
RoosterBio and Secretome advance scalable cell therapy manufacturing with a new 50L bioreactor process for STM-01 clinical trials.
Capricor Therapeutics is coordinating with the FDA on regulatory steps for its Duchenne therapy, with updates expected soon.
